Dr. Bhatia Medical Coaching Institute (DBMCI) has announced a ground breaking joint venture with M3, Inc., a prominent J...
Japanese pharma major Eisai Co. has made an agreement to collaborate with the Department of Medical Services (DMS), Mini...
Japan-based PRISM BioLab, a leading discovery and development biotechnology company designing small molecule inhibitors ...
Daiichi Sankyo has reached an agreement with Japan’s Ministry of Health, Labour and Welfare (MHLW) to supply the o...
Japan-based Fujitsu Limited and Delight Health, a Bay Area startup, have announced that Fujitsu will license its Topolog...
Japan-based Astellas Pharma and US-based startup Propella Therapeutics have entered into a merger agreement pursuant to ...
Japan-based University of Tsukuba and Astellas Pharma have signed a letter of confirmation regarding a strateg...
Japan-based iPark Institute has announced the signing of a groundbreaking business agreement with South Korea's Small an...
Japanese firm Fujitsu has signed a General Action Protocol with the Regional Government of Andalusia, Spain to establish...
Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo ...
Duke-NUS Medical School (Duke-NUS) in Singapore and IPGaia, Inc. (IPG) in Japan have signed an agreement to jointly adva...
Japan-headquartered Global Health Innovative Technology Fund (GHIT Fund) and Switzerland-based Medicines Patent Pool (MP...
Japan based Shionogi and US based Apnimed, Inc. have agreed to establish a joint venture (JV) company, Shionogi-Apnimed ...
I Peace, Inc., specialising in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies based in Palo Alto...
Japan-headquartered pharmaceutical company Daiichi Sankyo's Board has passed a resolution on the basic policy for ...
US-based startup AnHeart Therapeutics has entered into an exclusive license agreement with Nippon Kayaku to market ...
Japan-based companies Sumitomo Pharma and AlphaNavi Pharma have announced that AlphaNavi has exercised its option rights...
Debiopharm International SA, Yakult Honsha and Takata Pharmaceutical have agreed that Yakult Honsha will transfer ...
